Company Filing History:
Years Active: 2025
Title: The Innovations of Ming-jin Jheng
Introduction
Ming-jin Jheng is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of targeted therapies for cancer treatment. His innovative work has led to the creation of a unique antibody that holds promise for improving patient outcomes.
Latest Patents
Ming-jin Jheng holds a patent for a CLDN18.2-targeting antibody, which is a bispecific antibody designed for therapeutic use. The patent details a single-domain heavy-chain antibody that exhibits high affinity for tumor cells expressing CLDN18.2. This invention is notable for its ability to induce high endocytic activity, which is crucial for effective cancer treatment. The bispecific antibody targets both CLDN18.2 and CD3, optimizing the release of common cytokines to reduce adverse effects associated with cytokine release syndrome (CRS).
Career Highlights
Ming-jin Jheng is currently employed at Harbour Biomed (Shanghai) Co., Ltd. His work at this innovative company focuses on advancing antibody therapies that can significantly impact cancer treatment. His expertise in antibody engineering and therapeutic applications has positioned him as a key figure in the biotechnology sector.
Collaborations
Ming-jin collaborates with talented professionals in his field, including Yongqiang Wang and Yun Zhang. These collaborations enhance the research and development efforts at Harbour Biomed, fostering an environment of innovation and discovery.
Conclusion
Ming-jin Jheng's contributions to the field of biotechnology, particularly through his patented innovations, demonstrate his commitment to advancing cancer therapies. His work continues to inspire and pave the way for future developments in targeted treatments.